Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 34

Results For "formulation"

800 News Found

Zydus receives final approval from the USFDA for Diclofenac Sodium and Misoprostol Delayed Release Tablets
Drug Approval | June 14, 2023

Zydus receives final approval from the USFDA for Diclofenac Sodium and Misoprostol Delayed Release Tablets

Diclofenac Sodium and Misoprostol Delayed Release Tablets USP, 50mg/200 mcg and 75mg/200 mcg had annual sales of USD 13 mn in the United States


Biostar announces first patient enrolled for Phase 1 study of Utidelone Capsule
News | June 13, 2023

Biostar announces first patient enrolled for Phase 1 study of Utidelone Capsule

UTD2 is the world's first oral epothilone microtubule inhibitor


Asence Pharma commences new plant at Ranoli, Vadodara
News | June 10, 2023

Asence Pharma commences new plant at Ranoli, Vadodara

The new API plant is set up to meet all domestic and international regulatory standards and will manufacture niche molecules that have a global requirement


Cosette Pharmaceuticals acquires Intrarosa from Endoceutics
News | June 09, 2023

Cosette Pharmaceuticals acquires Intrarosa from Endoceutics

Acquisition accelerates Cosette’s women’s health portfolio; with a differentiated, commercial stage, patent protected product


Zydus receives final approval from USFDA for Esomeprazole Magnesium
Drug Approval | June 09, 2023

Zydus receives final approval from USFDA for Esomeprazole Magnesium

Esomeprazole Magnesium for Delayed-Release Oral Suspension, 20 mg and 40 mg had annual sales of USD 42 mn in the United States (IQVIA MAT April 2023)


Zydus receives final approval from the USFDA for Tadalafil Tablets USP
Drug Approval | June 08, 2023

Zydus receives final approval from the USFDA for Tadalafil Tablets USP

Tadalafil Tablets USP, 20 mg had annual sales of USD 61 mn in the United States (IQVIA MAT April 2023)


JB Pharma completes 1 year of its identity launch
News | June 07, 2023

JB Pharma completes 1 year of its identity launch

Records revenue growth of 22% to Rs. 762 crores in Q4 FY23 and grew 30% to Rs. 3149 crores in FY23


Dr. Reddy's completes Phase I study (IV route) of a proposed biosimilar of tocilizumabp
News | June 06, 2023

Dr. Reddy's completes Phase I study (IV route) of a proposed biosimilar of tocilizumabp

The successful outcome of this study represents an important milestone in Dr. Reddy's commitment to make highquality biosimilar products more accessible and affordable


Evonik launches updated Biolys product for animal feeds
News | June 05, 2023

Evonik launches updated Biolys product for animal feeds

The new Biolys provides higher concentration of L-lysine


Evonik launches next-generation peptide for biopharma applications
News | June 02, 2023

Evonik launches next-generation peptide for biopharma applications

One thousand times more soluble than L-cystine at neutral pH